ASCO 2026 Preview: Key Data and Trends in Cancer Research

ASCO 2026 Preview: Key Data and Trends in Cancer Research

An ASCO preview: what to watch for at cancer research's biggest meeting. This ASCO preview highlights crucial developments in cancer research, focusing on key data presentations and emerging trends that will shape the oncology landscape. Investors and BD teams should monitor these advancements for strategic insights. Revolution Medicines' pancreatic cancer candidate and Akeso's ivonescimab top the list of readouts expected to move markets in Chicago.

Key ASCO 2026 Highlights

The ASCO Annual Meeting remains the single most consequential catalyst event in oncology, where clinical data can redefine competitive positioning overnight. More than 43,000 attendees have registered for this year's gathering in Chicago, and two companies sit at the center of the pre-meeting buzz: Revolution Medicines, with its RAS-blocking candidate targeting pancreatic cancer, and Akeso, whose ivonescimab data will be closely scrutinized by investors tracking the PD-1/CTLA-4 bispecific space.

Both programs earned prominent placement in STAT's preview of the meeting, underscoring the weight these readouts carry for their respective pipelines. Beyond individual data drops, ASCO 2026 is expected to spotlight biomarker-driven lung cancer care, antibody-drug conjugates, and late-stage trials advancing precision oncology — themes that will frame deal-making and R&D prioritization for quarters to come.

What Data Is Revolution Medicines Presenting on Its Pancreatic Cancer Drug?

Revolution Medicines enters ASCO 2026 as the clear headliner. The company's RAS-blocking therapeutic candidate targets pancreatic cancer, an indication where meaningful clinical progress has been stubbornly rare and unmet need remains acute. Pancreatic ductal adenocarcinoma continues to carry a five-year survival rate below 12%, and any signal of efficacy in this space commands outsized attention from both the clinical and investment communities.

The mechanism — direct RAS pathway inhibition — represents a differentiated approach in a field where KRAS G12C inhibitors like Amgen's Lumakras (sotorasib) and Mirati's Krazati (adagrasib) have already validated the target but left significant room for next-generation agents. Revolution's broader RAS(ON) platform aims to address multiple KRAS mutations beyond G12C, potentially expanding the addressable patient population considerably. ASCO data will reveal whether the preclinical promise translates into clinical proof of concept.

The competitive landscape in pancreatic cancer has intensified. Bristol-Myers Squibb, Roche, and several ADC-focused biotechs are advancing programs in the space. Any compelling efficacy signal from Revolution could trigger partnership discussions or accelerate competitive responses from larger oncology players seeking to bolster their gastrointestinal cancer franchises. For a deeper look at the trial design, readers can consult the relevant study listings on ClinicalTrials.gov.

How Is Akeso Positioning Ivonescimab Ahead of ASCO 2026?

Akeso's ivonescimab, a PD-1/CTLA-4 bispecific antibody, represents one of the most closely watched programs heading into ASCO 2026. The drug has already generated significant interest following earlier data suggesting competitive efficacy against Merck's Keytruda in certain NSCLC settings. Updated results at ASCO will be critical for Akeso's strategic positioning, particularly as the company navigates its co-development partnership with Summit Therapeutics for ex-China rights.

The bispecific antibody space has become a key battleground in immuno-oncology. With checkpoint inhibitor monotherapy maturing as a modality, the industry has pivoted toward combination strategies and multi-specific constructs that can improve response rates while managing toxicity. Ivonescimab's dual-targeting approach — simultaneously blocking PD-1 and CTLA-4 through a single molecule — could offer a differentiated safety and efficacy profile compared to traditional combination regimens.

For Akeso, strong ASCO data would strengthen its hand in ongoing and future partnership negotiations. The company has already demonstrated an appetite for creative deal structures, and compelling clinical readouts could attract interest from major oncology players seeking next-generation immuno-oncology assets. Conversely, underwhelming data would raise questions about the drug's competitive ceiling in an increasingly crowded field. Investors tracking the regulatory pathway for bispecific antibodies in oncology can review relevant guidance documents on FDA.gov.

What Broader Trends in Oncology Will ASCO 2026 Highlight?

Beyond individual company readouts, ASCO 2026 is expected to reinforce several structural shifts in cancer research. Biomarker-driven care continues to move from aspiration to standard practice, with companion diagnostics increasingly embedded in trial design and regulatory strategy. This trend has direct implications for BD teams evaluating acquisition targets — assets without clear biomarker strategies face steeper commercialization hurdles.

Antibody-drug conjugates remain a dominant theme, with companies like Daiichi Sankyo, Pfizer (following its Seagen acquisition), and Merck advancing next-generation ADC platforms. The modality's expansion beyond HER2-positive breast cancer into tumor-agnostic or broader indications represents a significant market opportunity. ASCO data presentations will likely include updated efficacy and safety profiles for several ADC programs, informing competitive positioning across multiple tumor types.

Precision oncology advances — including liquid biopsy integration, minimal residual disease monitoring, and AI-driven treatment selection — are also expected to feature prominently. These enabling technologies are reshaping how trials are designed and how therapies are commercialized, creating both opportunities and disruption for established oncology franchises. The ASCO Meeting Library will host published abstracts and presentation slides as they become available.

How Will ASCO 2026 Data Reshape BD and Investment Strategies?

For BD teams and investors, ASCO 2026 functions as a real-time market signal generator. Positive data from Revolution Medicines could trigger a revaluation of RAS-targeted therapy assets across the sector, potentially accelerating M&A activity among companies with complementary pipeline positions. Akeso's ivonescimab readouts will inform the bispecific antibody competitive framework, with implications for companies like Regeneron, BeiGene, and others advancing similar constructs.

From a competitive intelligence standpoint, ASCO presentations provide granular data — response rates, duration of response, subgroup analyses, safety profiles — that enable direct head-to-head comparisons even in the absence of formal crossover trials. Analysts and BD teams should pay particular attention to overall survival data, which remains the gold standard for regulatory and commercial differentiation.

The meeting also serves as a barometer for emerging therapeutic modalities. Strong data from early-stage programs in areas like molecular glues, radiopharmaceuticals, or novel cell therapies can shift R&D investment priorities and partnership strategies for years to come. Companies with limited oncology exposure may find ASCO 2026 data compelling enough to enter the space through licensing or acquisition.

Key Takeaways

• Revolution Medicines' RAS-blocking pancreatic cancer candidate is the marquee ASCO 2026 readout, with potential to redefine the competitive framework in one of oncology's most challenging indications.
• Akeso's ivonescimab data will shape the bispecific antibody narrative and influence partnership dynamics in the PD-1/CTLA-4 space.
• Biomarker-driven trial design, ADC platform advances, and precision oncology technologies are structural trends that will frame BD and investment strategies well beyond this year's meeting.
• ASCO 2026 data will trigger near-term pipeline revaluations and could accelerate M&A activity among companies seeking to strengthen their oncology franchises.

Frequently Asked Questions

Related profiles

• ivonescimab
• Akeso
• Revolution

Related coverage

• ASCO 2026: Key Takeaways on Cancer Care Barriers and New Treatments
• ASCO 2026: Grief Takes Center Stage Amidst Cancer Data
• Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment